Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifapentine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 3/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.87 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.87 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.87 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifapentine SCHEMBL29448246 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL29913543 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL18842901 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL20032589 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL41591 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL41590 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL20033121 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL15472877 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL20769769 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL25876809 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121058-B1 | OXAZOLIDINONE COMPOUND AND ITS USE THEREOF AS AN ANTIBACTERIAL AGENT | MERCK SHARP & DOHME LLC (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-3965808-B1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | UNIV YEDITEPE (TR) | 2025-09-03 | — | — | EP | claimed |
| WO-2025125541-A1 | METHOD FOR PREDICTING THE RISK OF POST-OPERATIVE RECURRENCE OF A CANCER | ROSKILDE UNIVERSITET (DK) | 2025-06-19 | — | — | WO | claimed |
| CN-119892326-A | Method, device and medium for transmitting sounding reference signal | 北京小米移动软件有限公司 | 2025-04-25 | — | — | CN | claimed |
| US-20250119252-A1 | METHOD OF SOUNDING REFERENCE SIGNAL TRANSMISSION, COMMUNICATION METHOD AND SYSTEM, AND COMPUTER-READABLE MEDIUM | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-04-10 | — | — | US | claimed |
| US-20250108152-A1 | DRUG ELUTING POLYMER COMPOSED OF BIODEGRADABLE POLYMERS APPLIED TO SURFACE OF MEDICAL DEVICE | THE GENERAL HOSPITAL CORPORATION | 2025-04-03 | — | — | US | claimed |
| US-20240408070-A1 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING AUTISM | BORODY THOMAS J (AU) | 2024-12-12 | — | — | US | claimed |
| US-12115289-B2 | Drug eluting polymer composed of biodegradable polymers applied to surface of medical device | THE GENERAL HOSPITAL CORPORATION (US) | 2024-10-15 | — | — | US | claimed |
| EP-3331504-B1 | TABLET COMPOSITION FOR ANTI-TUBERCULOSIS ANTIBIOTICS | MANNING THOMAS (US) | 2024-08-28 | — | — | EP | claimed |
| EP-3288554-B1 | USE OF ANTIBIOTICS WITH SPECIFIC THERAPEUTIC ACTIVITIES COMBINED WITH THE SIMULTANEOUS USE OF LACTOBACILLI AND/OR BIFIDOBACTERIA WITH A NON-TRANSFERABLE ANTIBIOTIC RESISTANCE, HAVING THE SAME THERAPEUTIC INDICATION | PROBIOTICAL SPA (IT) | 2022-08-24 | — | — | EP | claimed |
| EP-3265083-B1 | SUBSTITUTED UREA DEPSIPEPTIDE ANALOGS AS ACTIVATORS OF THE CLPP ENDOPEPTIDASE | ST JUDE CHILDRENS RES HOSPITAL (US) | 2022-07-06 | — | — | EP | claimed |
| WO-2022138639-A1 | OPHTHALMIC COMPOSITION OF RIFAMYCIN, AND USE THEREOF | ビーエヌシー コリア カンパニー，リミテッド | 2022-06-30 | — | — | WO | claimed |
| EP-2999711-B1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS INC (US) | 2022-06-29 | — | — | EP | claimed |
| US-11343046-B2 | Method and device for receiving and sending reference signal, and computer-readable storage medium | XI'AN ZHONGXING NEW SOFTWARE CO., LTD. (CN) | 2022-05-24 | — | — | US | claimed |
| CN-114262344-A | Charged linkers and their use in conjugation reactions | 杭州多禧生物科技有限公司 | 2022-04-01 | — | — | CN | claimed |
| US-20220088012-A1 | COMBINATION THERAPY | Janssen Sciences Ireland Unlimited Company (IE) | 2022-03-24 | — | — | US | claimed |
| EP-3500254-B1 | PHARMACEUTICAL COMPOSITION CONTAINING POLYMYXIN B/TRIMETHOPRIM BASED THERAPEUTICS | UNIV ROCHESTER (US) | 2022-03-23 | — | — | EP | claimed |
| CN-215797754-U | Elevator detection system | 福建省中侨富士电梯有限公司 | 2022-02-11 | — | — | CN | claimed |
| US-20220040156-A1 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDER | CENTRE FOR DIGESTIVE DISEASES (AU) | 2022-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | IL1B, IL5, SERPINB1 | MAPT 2458/4885ABCB11 510/4885ABCC4 1500/4885 |
| US-20220088012-A1 | COMBINATION THERAPY | FNTB, CSF3R, IFNG | MAPT 2668/4885ABCB11 1940/4885ABCC4 1344/4885 |
| US-20220040156-A1 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDER | SFXN1, SFXN3, GRIN2D | MAPT 3676/4885ABCB11 1800/4885ABCC4 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.